The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
about
Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.Choosing first-line therapy for chronic lymphocytic leukemia.CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study.Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia.The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia.Changing paradigms in the treatment of chronic lymphocytic leukemia.Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies.Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.Rituximab for chronic lymphocytic leukemia.Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.Low-dose fludarabine increases rituximab cytotoxicity in B-CLL cells by triggering caspases activation in vitro.NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.
P2860
Q33375915-3B19A70C-3C7F-49BF-9DDF-FCF207A92A0DQ34016413-7D5561B8-F822-493B-8078-7430964AA2A4Q34310845-F9DD1498-35F2-4D3F-AECB-40B24CE85DBDQ35124844-2312F6C2-3456-4ADC-A26C-4BD2C5FAF368Q35717883-7A32959C-5D1A-46E4-95BE-BF65E64CEF04Q36097697-5CAF718B-DEFA-4F76-839B-B996E1D2FC32Q36420752-78407E93-C0A9-4CBD-908B-FD8F22FB5018Q36665330-2409A669-1A80-48B2-9AB2-0F820FCBB255Q36689156-CB7E65EF-B0FF-4E1E-8FD0-B7AFEBE7E6C6Q36849336-E29FB553-021E-49EF-9262-5229FE1A66BBQ37662198-6F36E037-CC9F-407A-8072-259E64EB0D03Q37799820-6DBFC95F-D61C-4156-996A-7C0A43ACAD5EQ37842484-F9FCDB42-9A62-4DE7-906E-9FB952B909DDQ37854714-A3DFD872-6688-40C0-B68B-8D1A3EF9DB7EQ37988562-E7535110-C792-4E68-A6DE-45C8AE0648B9Q38068932-41EE98C3-BA5B-449C-9E5C-2E0B55D8EDA3Q43225850-B933C75A-C8F2-481A-96CB-E8AFCD78AA17Q54345184-251BCB47-3328-40F1-9DD6-7B5CEC76D259
P2860
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The addition of rituximab to f ...... chronic lymphocytic leukemia.
@en
The addition of rituximab to f ...... chronic lymphocytic leukemia.
@nl
type
label
The addition of rituximab to f ...... chronic lymphocytic leukemia.
@en
The addition of rituximab to f ...... chronic lymphocytic leukemia.
@nl
prefLabel
The addition of rituximab to f ...... chronic lymphocytic leukemia.
@en
The addition of rituximab to f ...... chronic lymphocytic leukemia.
@nl
P2093
P2860
P50
P921
P356
P1433
P1476
The addition of rituximab to f ...... chronic lymphocytic leukemia.
@en
P2093
Antonio Bruno
Carla Mazzone
Giovanni Capelli
Giovanni Del Poeta
Laura Gianní
Luca Maurillo
Maria Antonietta Irno Consalvo
Maria Cantonetti
Maria Ilaria Del Principe
Sergio Amadori
P2860
P304
P356
10.1002/CNCR.21535
P407
P577
2005-12-01T00:00:00Z